Celldex Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Celldex Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-73.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 78% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 34%
Sales fell 34% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-34% / +65%In 3 years sales changed by -34% while total assets changed by +65%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-135.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 87% of Healthcare companies in United States.
Cash Cushion Ratio
+23%Cash, after subtracting all debt, equals 23% of its market value (net cash).
Higher than 64% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 73% of Healthcare companies in United States.
Tangible Net Worth Ratio
95%Of every $100 of net worth, $95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 80% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Celldex Therapeutics, Inc. made a loss over the last year. Celldex Therapeutics, Inc. owes $0.09 for every $1 it owns. Celldex Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCelldex Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.18The share price is 3.18 times Celldex Therapeutics, Inc.'s book value per share, higher than 58% of Healthcare companies in United States.
Market cap
$2.3 BThe total market value of all of Celldex Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 77% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$715 MWhat Celldex Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$9.10Net worth divided by the number of shares. The share price of $28.97 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
-43.9%Celldex Therapeutics, Inc. lost 43.9% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
Owes vs Owns
0.09×Celldex Therapeutics, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Dividend yield
NoneCelldex Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-78%Revenue fell 78% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Profit growth
LossCelldex Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-16748.0%Celldex Therapeutics, Inc. lost $16748 for every $100 of revenue.
Cash vs debt
Net cashCelldex Therapeutics, Inc. held $516 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Celldex Therapeutics, Inc.: $2.3 B ÷ $715 M (30 Jun 2026) = 3.2.
What is Celldex Therapeutics, Inc.'s return on equity?
Celldex Therapeutics, Inc. lost 43.9% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
How much does Celldex Therapeutics, Inc. owe compared with what it owns?
Celldex Therapeutics, Inc. owes $0.09 for every $1 it owns (low), lower than 88% of Healthcare companies in United States.
Does Celldex Therapeutics, Inc. pay a dividend?
No. Celldex Therapeutics, Inc. does not currently pay a dividend.
Is Celldex Therapeutics, Inc.'s revenue growing?
Revenue fell 78% in the year to Dec 2025, and shrank 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.